MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jgh.15412

Медицинская библиотека · Journal of gastroenterology and hepatology · 2021

Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.

Kong Fei, Wen Xiaoyu, Wen Xiaofeng, Wang Xiaozhong, Wu Guicheng, Lin Shide, Wang Li, Xing Huichun, Yan Xuebing, Zheng Sujun, Ning Qin, Wang Zheng, Zhang Liaoyun, Lin Jianmei, Tong Zhaowei, Huang Chengyu, Su Minghua, Tong Lixin, Jia Jidong, Xin Yongning, Zhu Qingjing, Wang Jing, Chen Li, Li Xiaowen, Wu Xuegang, Niu Duan, Liu Quan, Wei Wei, Zhang Yuexin, Li Guangming, Niu Junqi

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND AND AIM: This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis.

METHODS

Treatment-naive or interferon-experienced adult patients without cirrhosis were treated with a universal, combinational regimen of seraprevir 100 mg, twice daily and sofosbuvir 400 mg, once daily, for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response at week 12 after treatment (SVR12).

RESULTS

Overall, 205 patients with genotype 1 HCV infection without cirrhosis were enrolled from 23 sites, 202 of whom completed the full treatment and post-treatment course and 3 discontinued follow-up. In total, 27 patients (13.2%) were interferon experienced. SVR12 was achieved by 201 out of 205 (98.0% [95% CI, 95.1%, 99.5%]) patients, 100.0% of patients with genotype 1a, and 98.0% of genotype 1b. In the other exploratory study, SVR 12 was achieved by 100% patients with genotype 2 (n = 21), genotype 3 (n = 7), and genotype 6 (n = 8). The majority of adverse events were mild to moderate and transient and did not require a specific medical intervention.

CONCLUSIONS

The all-oral, ribavirin-free regimen of seraprevir and sofosbuvir is an effective and well-tolerated treatment option for Chinese patients mono-infected with HCV, including those with a history of interferon treatment.

Для цитирования: Kong Fei, Wen Xiaoyu, Wen Xiaofeng, Wang Xiaozhong, Wu Guicheng, Lin Shide, Wang Li, Xing Huichun, Yan Xuebing, Zheng Sujun, Ning Qin, Wang Zheng, Zhang Liaoyun, Lin Jianmei, Tong Zhaowei, Huang Chengyu, Su Minghua, Tong Lixin, Jia Jidong, Xin Yongning, Zhu Qingjing, Wang Jing, Chen Li, Li Xiaowen, Wu Xuegang, Niu Duan, Liu Quan, Wei Wei, Zhang Yuexin, Li Guangming, Niu Junqi. Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.. Journal of gastroenterology and hepatology. 2021. DOI: 10.1111/jgh.15412.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.